---
title: "Zhengye Biotechnology regains Nasdaq compliance with $1 minimum bid price rule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295103784.md"
description: "Zhengye Biotechnology has regained compliance with Nasdaq's $1 minimum bid price rule, eliminating the risk of delisting associated with this deficiency. Nasdaq confirmed that the company's shares closed at or above $1 for ten consecutive trading sessions from July 20 to August 4, following a notice received on May 29."
datetime: "2026-08-06T12:01:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295103784.md)
  - [en](https://longbridge.com/en/news/295103784.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295103784.md)
generator: "portal-rs"
---

# Zhengye Biotechnology regains Nasdaq compliance with $1 minimum bid price rule

-   Zhengye Biotechnology regained compliance with Nasdaq’s $1 minimum bid-price rule, removing the risk of a delisting process tied to the deficiency. \* Nasdaq confirmed the shares closed at $1 or higher for 10 consecutive sessions from July 20 to Aug. 4, following a May 29 notice. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608060800PRIMZONEFULLFEED9805088) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ZYBT.US](https://longbridge.com/en/quote/ZYBT.US.md)

## Related News & Research

- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296801308.md)
- [Global Brain leads investment in cancer detection startup MiRNDa](https://longbridge.com/en/news/296842692.md)
- [Inhibrx Biosciences (NASDAQ:INBX) Earns Buy Rating from Analysts at HC Wainwright](https://longbridge.com/en/news/296785368.md)
- [Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Hold" from Analysts](https://longbridge.com/en/news/296803920.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**